Evidence map›Paper›PMID 36851847›Full record

ArticleProtein science : a publication of the Protein Society2023

Additive energetic contributions of multiple peptide positions determine the relative promiscuity of viral and human sequences for PDZ domain targets.

Elise F Tahti, Jadon M Blount, Sophie N Jackson, Melody Gao, Nicholas P Gill, Sarah N Smith, Nick J Pederson, Simone N Rumph, Sarah A Struyvenberg, Iain G P Mackley and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. DexDesign: an OSPREY-based algorithm for designing de novo D-peptide inhibitors.Protein engineering, design & selection : PEDS · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Elise F TahtiDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Jadon M BlountDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Sophie N JacksonDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Melody GaoDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Nicholas P GillDepartment of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Sarah N SmithDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Nick J PedersonDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Simone N RumphDepartment of Biochemistry, Bowdoin College, Brunswick, Maine, USA.
Sarah A StruyvenbergDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Iain G P MackleyDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.
Dean R MaddenDepartment of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Jeanine F AmacherDepartment of Chemistry, Western Washington University, Bellingham, Washington, USA.ORCID 0000-0002-3646-7521
Western Washington University · USDartmouth College · USBowdoin College · US

Funding

Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEAN R MADDEN · 2018 to 2026
$13.9M
Preclinical development of CFTR stabilizers targeting the CAL PDZ domainR01DK101541 · NIDDK · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2014 to 2017
$1.9M
NIDDK NIH HHS P30 DK117469NIDDK NIH HHS R01 DK101541NIGMS NIH HHS P20 GM113132NIH HHS P20-GM113132NIH HHS R01-DK101541
6 · The paper itself

Abstract

Protein-protein interactions that involve recognition of short peptides are critical in cellular processes. Protein-peptide interaction surface areas are relatively small and shallow, and there are often overlapping specificities in families of peptide-binding domains. Therefore, dissecting selectivity determinants can be challenging. PDZ domains are a family of peptide-binding domains located in several intracellular signaling and trafficking pathways. These domains are also directly targeted by pathogens, and a hallmark of many oncogenic viral proteins is a PDZ-binding motif. However, amidst sequences that target PDZ domains, there is a wide spectrum in relative promiscuity. For example, the viral HPV16 E6 oncoprotein recognizes over double the number of PDZ domain-containing proteins as the cystic fibrosis transmembrane conductance regulator (CFTR) in the cell, despite similar PDZ targeting-sequences and identical motif residues. Here, we determine binding affinities for PDZ domains known to bind either HPV16 E6 alone or both CFTR and HPV16 E6, using peptides matching WT and hybrid sequences. We also use energy minimization to model PDZ-peptide complexes and use sequence analyses to investigate this difference. We find that while the majority of single mutations had marginal effects on overall affinity, the additive effect on the free energy of binding accurately describes the selectivity observed. Taken together, our results describe how complex and differing PDZ interactomes can be programmed in the cell.

Indexed as

Cystic Fibrosis Transmembrane Conductance RegulatorPDZ DomainsEntropyHumansPeptidesProtein BindingCystic Fibrosis Transmembrane Conductance RegulatorPeptidesbinding affinitiesCFTRHPV16motifsPDZpeptide-binding domainsprotein-protein interactionsselectivity determinantsvirus-PDZ interactions

Identifiers

PMID36851847
PMCPMC10022582
OpenAlexW4322617989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.